THINK INDIA JOURNAL

ISSN: 0971-1260
Vol-22-NO-30 Special Issue-December-2019

Current and Evolving Strategies For The Treatment of Diabetic Retinopathy

Mohanbir Singh, Rohan Chhabra, Deep Shikha Sharma*

School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab (India)–144411

*Address for correspondence: Deep Shikha Sharma, Assistant Professor (Pharmaceutics), School of Pharmaceutical Sciences, Lovely Professional University, Phagwara - 144411, Punjab, India. Phone: +91-9501828409. E mail id: deepshikha64@yahoo.com, deep.23570@lpu.co.in

ABSTRACT

Diabetes retinopathy (DR) is one of the main complications due to diabetes. DR will damage the retinal capillaries and block them, which causes the loss of vision. Different drugs and therapies are used for the treatment and prevention of the DR. The most commonly used treatment is laser technology and combination therapy, along with some drugs. But these drugs possess side effects in the form of cataract, glaucoma, and complete blindness of the eye. The main strategy to overcome In DR, medicines with minimum side effects or maximum therapeutic effects is used. This article emphasizes the current strategy used for the treatment of DR.

Keywords- Diabetes, diabetic retinopathy, herbal drugs, laser therapy

1. Introduction:

DR is a condition that occurs in people with diabetes havinghigher amount of sugar in the blood which can damage the retinal blood vessels. There will be swelling and leakage of the blood vessels. Abnormal growth of the blood vessels on the retina is called angiogenesis. All these changes can steal the vision. It mainly effect the people those have diabetes for more than 20 years [1].

As per IFD (International Federation of Diabetes), there will be 642 million people suffering from diabetes in the world in 2040, mainly in elder and young peoples. DR is thirdmain cause of

ISSN: 0971-1260
Vol-22-NO-30 Special Issue-December-2019

blindness in USA (United States of America). The individuals worldwide having diabetes can be increased from 171 million in year 2000 to 366 million in year 2030 [1].

According to International Diabetes Federation (IDF) 2019,about 463 million people worldwide were estimated to have diabetes were in the age group of 20-79 years. Among them, the portion of the people having type 2 diabetes mellitus is increasing in most countries, about 79% of the population lives in middle and low income countries. The highest number of diabetic patients is between 40 and 59 years of age. It is expected that by 2045, about 700 million people will be suffering from diabetes [2].

According to Centers for disease control and prevention (CDC) report provides current information on status of diabetes in USA. Itis also including information and data about diabetes, pre-diabetes, and quality of carenational and state trends. The rate of new case of diabetes among USA adults has decreased and among children and adolescents has increased. New diabetes resources have been developed to help health insurance and employers [3].

1.1 Types of DR

1.1.1-Proliferative Diabetic Retinopathy (PDR) or advanced diabetic retinopathy (ADR) – DR can advance to the more extreme sort, known as PDR. In this sort, harmed veins are being closedleads to development of new unusual retinal veins, and can spill into jam like substance that fills the focal point of eye. Inevitably, scar tissue invigorated by development of fresh recruits vessels make the retina isolate from the rear of eye. On off chance that the fresh recruits vessels meddle with the typical progression of liquid out from the eye, weight may develop inside eyeball. This can harm the nerve which conveys pictures from eye to mind (optic nerve), bringing about glaucoma.

1.1.2-Non-Proliferative Diabetic Retinopathy (NPDR) – The early stage of diabetic eye disease is called NPDR. Most of the people suffering from diabetes have NPDR. It is also called background retinopathy, which is an early stage of DR. In this there is leakage of tiny blood vessels within the retina [4].

ISSN: 0971-1260
Vol-22-NO-30 Special Issue-December-2019

1.2-Risk factors of DR-The person who is suffering from diabetes will lead to have DR.. The longer time period of diabetes will lead tomore risk of developing DR. Other risk factors are high blood pressure, , pregnancy, poor control sugar levelin the blood, tobacco use, cholesterol etc.

1.3-Symptom of DR-There aresomemajor symptoms of DR such asdark strings or spotting floating in vision, fluctuating vision, blurred vision, empty or dark areas in vision,impaired color vision, loss of vision etc.

1.4-Diagnosis of DR-DR can be diagnosed by exhaustive expanded eye test. In this test, eye drops put into the eyes for extentionof eyes, so that specialist can readily look into the eyes. In this diagnostic test eye doctor will observe retinal detachment, cataract, abnormal blood vessels, fatty deposits or blood in the retina,swelling, glaucoma, abnormalities in optic nerve, scar tissue, bleeding, angiogenesis, jelly-like substance in the center of eye, vision test, and eye pressure.

1.4.1 Fluoresce in angiography- With eyes enlarged photographs of the eyes will be taken by the specialist. He will infuse an uncommon color into the arm vein and accept more pictures as the color circles through the eye's veins. He can utilize these images to point outclosed veins.

1.4.2 Optical Coherence Tomography (OCT) - The sectional retinal images that shows retinal thickness was taken to find out the spillage into retinal tissue. This imaging test gives cross-tests used to screen how treatment is functioning [5].

1.5-Prevention of DR-Be that as it may, customary eye tests, great control of the glucose and early mediation for vision issues can counteract extreme vision misfortune.There are some preventive measures by which DR can be prevented.

1.5.1 Manage the diabetes-With the help of balanced dietand physical exercise during some portion of the everyday schedule diabetes can be cured which will indirectly cure DR. Attempt to get in any event 150 minutes of moderate oxygen consuming movement, for example, strolling every week. Take oral diabetes prescriptions or insulin as coordinated by the doctor.

1.5.2 Monitor the blood sugar level-The blood glucose level have to check and record the glucose level a few times each day increasingly visit estimations might be required the under pressure. Ask the specialist how frequently their is need to test the glucose.

ISSN: 0971-1260
Vol-22-NO-30 Special Issue-December-2019

1.5.3 G**lycosylated hemoglobin test**. This test is also known as glycosylated hemoglobin test which reflects normal glucose level for the 2-multi month time span before the test. A person who is suffering from diabetes undergo this test regularly to check the levels are within range or not. This is helpful in deciding diabetes medicine. This test is also used for diagnosis of diabetes. It tells the average level of blood sugar over the past 2 to 3 months.

1.5.4Keep blood pressure and cholesterol under control- By taking healthy foods, exercise on daily basis, blood pressure and cholesterol level can be maintained to prevent DR [6].

1.6-Treatment of DR-Treatment generally depends on the sort of DR have and how serious it is, is equipped to easing back or halting movement of the condition.

1.6.1 Early DR-In any case, the eyes have gentle or moderate no PDR may not require treatment immediately. Specialist will intently screen the eyes to decide when may require treatment. When DR is gentle or moderate, great glucose control can normally slow the movement.

1.6.2 Advanced DR- In the event that they have PDR or macular edema, the need brief careful treatment. Contingent upon the particular issues with the retina, choices may incorporate:

1.6.2.1Photocoagulation- This laser treatment also called central laser treatment which will stop or slow the spillage of blood and liquid in the eye. During the strategy, spills from unusual veins are treated with laser consumes. Central laser treatment is generally done in the specialist's office or eye center in a solitary session. Whenever had obscured vision from macular edema before medical procedure, the treatment probably won't restore the vision to typical, however it's probably going to lessen the opportunity the macular edema may intensify.

1.6.2.2Pan retinal photocoagulation- This laser treatment, otherwise called dissipate laser treatment, can shrivel the irregular veins. In this the zones of the retina away from the macula are treated with dissipated laser consumes. This influences the irregular fresh recruits vessels to therapist and scar.It is typically finished with the specialist's office or eye center in at least two sessions. The vision can be hazy for about a day after the system. Some loss of fringe vision or night vision after the methodology is conceivable.

ISSN: 0971-1260
Vol-22-NO-30 Special Issue-December-2019

1.6.2.3Vitrectomy-This technique utilizes a minor entry point into the eye to expel blood from the center of the eye just as scar tissue that are pulling on the retina. It is done by medical procedure focus or emergency clinic utilizing neighborhood or general anesthesia [7].

1.7-Complications of DR- There are some complications related to the DR. It involves abnormal retinal blood vessels growth called angiogenesis. The unusual veins related with DR animate the scar tissue development, with which the retina can be pulled away from the rear of the eyecalled retinal detachment. This also produces spots drifting in the vision, light flashes or extreme vision misfortune. -The fresh recruits vessels may seep into jam like substance that fills the focal point of the eyei.e. vitreous hemorrhage. In progressively serious cases, vitreous hole can be filled with blood and totally hinder vision. Fresh recruits vessels may develop in front piece of eye and middle with the typical progression of liquid out of eye, making pressure in eye develop (glaucoma). This can harm nerve which conveys pictures from eye to cerebrum (optic nerve). DR, glaucoma or both can result in complete vision loss [8].

2. Different drugs used in DR

2.1 Anti-VEGF drugs- Anti-VEGF stands for anti-vascular endothelial growth factor. The term ‘anti’ means against and ‘vascular’means blood vessels. These are Avastin (Bevacizumab), Lucentis (Ranibizumab), Eylea (aflibercept) [9]. The medications lessen macular edema and expansion (vein development) in DR, yet their impact for the most part wears off. To keep great sight in the long haul, the diabetes and pulse (BP) must be controlled: the medications are helpful for use while patients are attempting to control their diabetes and BP. The Anti-VEGFs are administered by injection into the vitreous cavity of the eyeball details. The drug remains there for 4-8 weeks.Lucentis/Avastin 3 infusions every month separated, at that point month to month OCT, assessments, and in the event that the macular edema re-amasses, at that point infuse 2-3 times and proceed. After the three stacking infusions, no infusions required if there is no edema.Eyelea- This isn't in ordinary use for DR, yet would most likely be utilized at the comparative time interims.Against VEGF infusions began early will keep up great vision; the treatment is useful. In spite of the fact that for good sight without infusions great diabetic control, low pulse, not smoking, wellbeing diet, are on the whole basic. Infusions should be begun ahead of schedule before serious macular edema creates, and with development and rehashed infusions,

ISSN: 0971-1260
Vol-22-NO-30 Special Issue-December-2019

and infrequent laser, the retina can stay dry without spillage or new vessels. So notwithstanding great diabetic control, we have to keep on identifying retinopathy early, and start infusion treatment early [10].

2.2 Steroid injections- All these are infusions given in the eyeball itself. Triamcinolone is a normal liquid infusion; heOsardex and illuvian are moderate discharge embeds.Triamcinolone is benefitial for short term use, particularly for post cataract macular edema [11]. There is a risk of glaucoma. Losardexhelps, but 100% patients developing, and there is a glaucoma risk. Past reports showed that this medication would be useful yet there are not many reports other than case reports. Later reports demonstrate no long haul advantage [12].

3. Advancement in treatment of DR

There are some treatment options available for management of DR [13]. Laser treatment is being used in cases of PDR for the treatment of angiogenesis at the back of the eye (retina), and to stabilize some cases of maculopathy. Eye injection is used in case of severe maculopathy i.e. threatening eye sight. Surgery of the eye being done to remove blood or scar tissue from the eye when laser therapyis not feasible because retinopathy is too advanced [14].

3.1. Laser treatment- It is utilized to treat fresh recruits vessels at the rear of the eyes in the propelled DR phases. This is done in light of the fact that the fresh recruits vessels will in general be frail and regularly cause eye seeping. Treatment can help balance out adjustments in the eyes brought about due to diabetes and stop the vision deteriorating, in spite of the fact that it won't ordinarily improve the sight [15].

Side effects-It has some side effects which will stay up to few hours. These are increase sensitivity to light,blurred vision.Sunglasses can be used until the eyes have adjusted [16].

3.2 Eye surgery- In case of diabetic retinopathic eye, jelly like substance which is transparent in nature that fills the space behind the lens of the eyes calledvitreous humour can be removed by the help of eye surgery. This is also called vitreoretinal surgery which is usually carried out under local anesthetic and sedation [17].

ISSN: 0971-1260
Vol-22-NO-30 Special Issue-December-2019

Side effects- It includes cataract, retinal detachment, fluid build-up in the cornea (outer layer at the front of the eye), bleeding into the eye, eye infection etc. [18].

3.3 Photocoagulation. This laser treatment, otherwise called central laser treatment, can stop or slow the spillage of blood and liquid in the eye. During the system, spills from unusual veins are treated with laser consumes.Central laser treatment is typically done in the specialist's office or eye center in a solitary session [19]. Whenever had obscured vision from macular edema before medical procedure, the treatment probably won't restore the vision to typical, however it's probably going to decrease the opportunity the macular edema may decline. In this the territories of the retina away from the macula are treated with dissipated laser consumes.It is generally done in the specialist's office or eye center in at least 2 sessions. The vision will be foggy for about one day after the strategy. Some loss of fringe vision or night vision after the strategy is conceivable [20, 21].

CONCLUSION

DR is a leading cause of blindness and a large population is suffering from this disease. For prevention or control of DR in the diabetic patient's glucose level, lipid level, blood pressure must be decreased. As laser therapy is not very effective, some suitable drugs are used for the treatment of DR. Both herbal and allopathic drugs are used via intra-vitreal route, implants and eye drops, Anti- VEGF agents and corticosteroids are mainly used alone or in combination therapy and also with laser therapy. There are still a limited number of therapies available at present for the treatment of DR. The best medication for DR treatment should be long-lasting, highly therapeutic, and safe. DR involves inflammation and ischemia. After retinopathy, early and regular treatment must be given to the patient to prevent loss of vision. After treatment, there will be improvement in the vision of DR patient. Therefore, it was concluded that DR can be treated at earlier stages.

REFERENCES

1. https://www.google.co.in/search?q=Eye+HAVING+DIABETIC+RETINOPATHY&source=lnms&tbm=isch&sa=X&ved=0ahUKEwj81rrjpoLdAhUIcCsKHd1kB4oQ_AUIC

ISSN: 0971-1260
Vol-22-NO-30 Special Issue-December-2019

igB&biw=1366 &bih=631#imgrc=yr-rT_T08g5mCM:(assessed on 23-08-2018 9:41AM)

2. IDF Diabetes Atlas, 2019. 9th ed. Update. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.html
3. Sharma, D.S., Wadhwa, S., Kumar, S. K., Thakur, D., Arya, K.R., Khursheed R., 2019. Current strategies and future perspective for the effective treatment of diabetic retinopathy. Current drug therapy. **DOI** : 10.2174/1574885514666191007101007 (https://doi.org/10.2174/1574885514666191007101007)
4. Wilkinson CP,Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110:1677–82.
5. NIH National Eye Institute. Facts about diabetic eye disease; 2015. Available from: https://nei.nih.gov/health/diabetic/ retinopathy.
6. Kim, J.H., Kim, J.H., Kim, K.W., Kim, M.H. and Yu, Y.S., 2009. Intravenously administered gold nanoparticles pass through the blood–retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology, 20(50), pp.505101.
7. Singh, S.R., Grossniklaus, H.E., Kang, S.J., Edelhauser, H.F., Ambati, B.K. and Kompella, U.B., 2009. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene therapy, 16(5), pp.645.
8. Campbell, M., Nguyen, A.T., Kiang, A.S., Tam, L.C., Gobbo, O.L., Kerskens, C., Dhubhghaill, S.N., Humphries, M.M., Farrar, G.J., Kenna, P.F. and Humphries, P., 2009. An experimental platform for systemic drug delivery to the retina. Proceedings of the National Academy of Sciences, 106(42), pp.17817-17822.
9. Marashi A. Using anti VEGF in Diabetic retinopathy. Advances in Ophthalmology & Visual System. 2016; 4 (4):1-5.
10. Papavasileiou E. Role of Anti-VEGF in Diabetic Macular Edema. Journal of Endocrinology and Diabetes.2015; 2 (1): 1-4.
11. Susanne Althauser Diabetic eye disease-screening and treatment options; 2014. Available from: http://www.totalhealth. co.uk/clinical-experts/miss-susanne-althauser/diabetic- eye-disease-screening-and-treatment-options.

ISSN: 0971-1260
Vol-22-NO-30 Special Issue-December-2019

12. Elakkiya M, Selvaraj K and Kuppuswamy G. Current and Emerging Therapies for the Management of Diabetic Retinopathy. Journal of Applied Pharmaceutical Science. 2017; 7 (09): 243-251.

13. Gaudana, R., Ananthula, H.K., Parenky, A. and Mitra, A.K., 2010. Ocular drug delivery. The AAPS journal, 12(3), pp.348-360.

14. Sigurdsson, H.H., Konráðsdóttir, F., Loftsson, T. and Stefansson, E., 2007. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. ActaOphthalmologicaScandinavica, 85(6), pp.598-602.

15. Koevary, S.B., 2003. Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. Current drug metabolism, 4(3), pp.213-222.

16. Inoue, J., Oka, M., Aoyama, Y., Kobayashi, S., Ueno, S., Hada, N., Takeda, T. and Takehana, M., 2004. Effects of dorzolamide hydrochloride on ocular tissues. Journal of ocular pharmacology and therapeutics, 20(1), pp.1-13.

17. Furrer, E., Berdugo, M., Stella, C., Behar-Cohen, F., Gurny, R., Feige, U., Lichtlen, P. and Urech, D.M., 2009. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti–TNF-α single-chain antibody, upon topical administration to the rabbit eye. Investigative ophthalmology & visual science, 50(2), pp.771-778.

18. https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/symptoms causes/syc-20371611(assessed on 02-09-2018 6:10PM)

19. https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/diagnosis-treatment/drc-20371617:(assessed on 12-09-2018 5:15PM)

20. .http://www.diabeticretinopathy.org.uk/drugtreatment.htm:(assessed on 21-09-2018 4:12PM)

21. Mohan V, Shah SN, Joshi SR, Seshiah V, Sahay BK, Banerjee S, et al. Current status of management, control, complications and psychosocial aspects of patients with diabetes in India: Results from the DiabCare India 2011 Study. Indian J EndocrinolMetab.2014;18:370.